Nat Rev Dis Primers. 2024 Jun 27;10(1):46. doi: 10.1038/s41572-024-00535-9.
NO ABSTRACT
PMID:38937486 | DOI:10.1038/s41572-024-00535-9
Recent Content
- Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
- Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma
- Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
- Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
- Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
- Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
- Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
- Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
- High WEE1 expression is independently linked to poor survival in multiple myeloma
- Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis